A Price Worth Paying: Hodgkin’s Lymphoma in a Crohn’s Disease Patient Treated with Azathioprine and Infliximab
DOI:
https://doi.org/10.14738/bjhmr.112.16816Keywords:
inflammatory bowel disease, non-Hodgkin’s lymphoma, Hodgkin’s Lymphoma, infliximab, azathioprine, Crohn’s disease, Ulcerative colitisAbstract
Malignancy in patients with inflammatory bowel disease (IBD) is ranked second behind cardiovascular diseases as the leading cause of death. People with IBD are prone to develop a variety of extraintestinal malignancies, particularly lymphomas. Many of these malignancies are non-Hodgkin lymphomas (NHL). Hodgkin lymphoma (HL) is a rather uncommon lymphoproliferative condition to occur in IBD. To date, there have been just a few cases of HL in IBD patients reported in the literature. Modern treatment regimen for Crohn’s disease (CD) has helped prevent enterectomy, intestinal perforation, or stenosis. Thiopurine is a proven maintenance therapy for CD, while tumour necrosis factor (TNF) inhibitors are effective for remission induction and maintenance treatment. Despite the increased likelihood of malignancy associated with treating CD with these agents, the risk is worth the complications. As these patients require long-term treatment to keep the disease at bay. Here we report a case of HL developing in a patient with CD being treated with both azathioprine and infliximab. The occurrence of HL in IBD patients should be considered a complication to therapy, especially if they are subjected to long-term treatment with these agents.
References
Beral V, Newton R. Overview of the epidemiology of immunodeficiency-associated cancers. J Natl Cancer Inst Monogr. 1998;(23):1-6.doi:10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A024164
Lo B, Zhao M, Vind I, Burisch J. The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A 180 Elmijbri, F. F., El-Magbri, M., Hermiz, J., Summad, S. H., & Magbri, A. (2024). A Price Worth Paying: Hodgkin’s Lymphoma in a Crohn’s Disease Patient Treated with Azathioprine and Infliximab. British Journal of Healthcare and Medical Research, Vol - 11(2). 177-181. Systematic Review and Meta-analysis of Population-based Cohort Studies. Clin Gastroenterol Hepatol. 2021;19(6):1117-1138.e19. doi:10.1016/j.cgh.2020.08.015
Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma. 2007;48(7):1410-1413. doi:10.1080/10428190701345433
Bucher C, Degen L, Dirnhofer S, et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut. 2005;54(5):732. doi:10.1136/gut.2004.059352
Mahé E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149(1):170-173. doi:10.1046/J.1365-2133.2003.05384.X
Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut. 2006;55(2):228. doi:10.1136/GUT.2005.075937
Nakashima C, Tanioka M, Takahashi K, Miyachi Y. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. Clin Exp Dermatol. 2008;33(4):437-439. doi:10.1111/J.1365-2230.2007.02683.X
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999;117(6):1433-1437. doi:10.1016/S0016-5085(99)70294-5
Musso M, Porretto F, Crescimanno A, BondÌ F, Polizzi V, Polizzi R. Crohn’s disease complicated by relapsed extranodal Hodgkin’s lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant. 2000;26(8):921-923. doi:10.1038/SJ.BMT.1702621
Palli D, Trallori G, Bagnoli S, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119(3):647-653. doi:10.1053/gast.2000.16487
Wong NACS, Herbst H, Herrmann K, et al. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. J Pathol. 2003;201(2):312-318. doi:10.1002/PATH.1442
Kumar R, Gandhi R. Reasons for cancellation of operation on the day of intended surgery in a multidisciplinary 500 bedded hospital. J Anaesthesiol Clin Pharmacol. 2012;28(1):66-69. doi:10.4103/0970-9185.92442
Bai M, Katsanos K, Economou M, et al. Rectal Epstein-Barr virus-positive Hodgkin’s lymphoma in a patient with Crohn’s disease: case report and review of the literature. Scand J Gastroenterol. 2006;41(7):866-869. doi:10.1080/00365520500529629
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE, Dickson M, Balkwill AM. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (London, England). 1994;343(8908):1249-1252. doi:10.1016/S0140-6736(94)92150-4
Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn’s disease. N Engl J Med. 1994;331(13):883-884. doi:10.1056/NEJM199409293311321
Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118(6):1018-1024. doi:10.1016/S0016-5085(00)70353-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fatma F. Elmijbri, Mariam El-Magbri, Joshua Hermiz, Sahar H. Summad, Awad Magbri
This work is licensed under a Creative Commons Attribution 4.0 International License.
